AG 85: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 135564900 |
| CHEMBL ID | 299928 |
| MeSH ID | M0246935 |
| Synonym |
|---|
| ag 85 (pharmaceutical) |
| CHEMBL299928 , |
| 6-({[4-(indole-1-sulfonyl)-phenyl]-prop-2-ynyl-amino}-methyl)-2-methyl-3h-quinazolin-4-one |
| bdbm50012240 |
| 6-[(4-indol-1-ylsulfonyl-n-prop-2-ynylanilino)methyl]-2-methyl-1h-quinazolin-4-one |
| 538zz20tpy , |
| 152503-91-8 |
| 1-((4-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)phenyl)sulfonyl)-1h-indole |
| 1h-indole, 1-((4-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)phenyl)sulfonyl)- |
| ag-85 |
| 1-((4-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinl)methyl)-2-propynylamino)phenyl)sulfonyl)-1h-indole |
| 1h-indole, 1-((4-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinl)methyl)-2-propynylamino)phenyl)sulfonyl)- |
| ag 85 |
| unii-538zz20tpy |
| n-(n4-((3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)-n4-(prop-2-ynyl)sulfanilyl)indole |
| DTXSID70165039 |
| 6-(((4-(1h-indol-1-ylsulfonyl)phenyl)-2-propyn-1-ylamino)methyl)-2-methyl-4(3h)-quinazolinone |
| 4(3h)-quinazolinone, 6-(((4-(1h-indol-1-ylsulfonyl)phenyl)-2-propyn-1-ylamino)methyl)-2-methyl- |
| 6-[(4-indol-1-ylsulfonyl-n-prop-2-ynylanilino)methyl]-2-methyl-3h-quinazolin-4-one |
| cid 127860 |
| 6-(((4-((1h-indol-1-yl)sulfonyl)phenyl)(prop-2-yn-1-yl)amino)methyl)-2-methylquinazolin-4(3h)-one |
| PD160655 |
| AKOS040750178 |
| 6-({[4-(1h-indole-1-sulfonyl)phenyl](prop-2-yn-1-yl)amino}methyl)-2-methyl-3,4-dihydroquinazolin-4-one |
| Excerpt | Reference |
|---|---|
| "A lyophilized, parenteral, liposomal dosage form was developed for an insoluble novel antitumor agent." | ( Liposomal formulations of a novel antitumor agent: drug loading and optimization. Johnston, A; Pavliv, L; Tyle, P, ) |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thymidylate synthase | Escherichia coli | Ki | 0.1500 | 0.0030 | 0.0687 | 0.1500 | AID211633 |
| Thymidylate synthase | Homo sapiens (human) | Ki | 0.0690 | 0.0001 | 0.3435 | 3.0000 | AID212460 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thymidylate synthase | Escherichia coli | Kii | 0.1900 | 0.0051 | 0.0668 | 0.1900 | AID211635 |
| Thymidylate synthase | Homo sapiens (human) | Kii | 0.0620 | 0.0100 | 0.0277 | 0.0620 | AID212464 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| mRNA regulatory element binding translation repressor activity | Thymidylate synthase | Homo sapiens (human) |
| thymidylate synthase activity | Thymidylate synthase | Homo sapiens (human) |
| folic acid binding | Thymidylate synthase | Homo sapiens (human) |
| protein homodimerization activity | Thymidylate synthase | Homo sapiens (human) |
| sequence-specific mRNA binding | Thymidylate synthase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Thymidylate synthase | Homo sapiens (human) |
| cytoplasm | Thymidylate synthase | Homo sapiens (human) |
| mitochondrion | Thymidylate synthase | Homo sapiens (human) |
| mitochondrial inner membrane | Thymidylate synthase | Homo sapiens (human) |
| mitochondrial matrix | Thymidylate synthase | Homo sapiens (human) |
| cytosol | Thymidylate synthase | Homo sapiens (human) |
| mitochondrion | Thymidylate synthase | Homo sapiens (human) |
| cytosol | Thymidylate synthase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID44029 | Inhibition of cellular growth against human (CCRF-CEM) leukemias (ATCC) deficient in thymidine kinase. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| AID212464 | Inhibition of human Thymidylate synthase (Kii) | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| AID98342 | Inhibition of cellular growth against mouse (L1210) deficient in thymidine kinase. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| AID72899 | Inhibition of cellular growth against human adenocarcinoma (GC3/M TK-) deficient in thymidine kinase. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| AID211633 | Inhibition of Thymidylate synthase of Escherichia coli (Ki) | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| AID211635 | Inhibition of Thymidylate synthase of Escherichia coli (Kii) | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| AID212460 | Inhibition of human Thymidylate synthase (Ki) | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Design of enzyme inhibitors using iterative protein crystallographic analysis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (37.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (62.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||